1. Single-Agent Pixantrone as a Bridge to Autologous Stem Cell Transplantation in a Patient with Refractory Diffuse Large B-Cell Lymphoma
- Author
-
Giovanni Serio, Lorena Appio, Elisabetta Vassenna, Martina Chiarucci, Carlo Landoni, Marco Bregni, Vanda Bertolli, Giovanni Crovetti, and Maria La Targia
- Subjects
Oncology ,Male ,medicine.medical_specialty ,Vincristine ,Lymphoma, B-Cell ,medicine.medical_treatment ,Hematopoietic stem cell transplantation ,Transplantation, Autologous ,Ventricular Function, Left ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Autologous stem-cell transplantation ,immune system diseases ,Bone Marrow ,hemic and lymphatic diseases ,Internal medicine ,Positron Emission Tomography Computed Tomography ,Drug Discovery ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Refractory Diffuse Large B-Cell Lymphoma ,Humans ,Topoisomerase II Inhibitors ,Pharmacology (medical) ,Cyclophosphamide ,Pharmacology ,Pixantrone ,business.industry ,Hematopoietic Stem Cell Transplantation ,General Medicine ,Middle Aged ,Isoquinolines ,Transplantation ,Infectious Diseases ,chemistry ,Doxorubicin ,030220 oncology & carcinogenesis ,Cytarabine ,Prednisone ,Rituximab ,Lymph Nodes ,business ,030215 immunology ,medicine.drug - Abstract
Aggressive non-Hodgkin lymphoma is associated with poor long-term survival after relapse or resistance to chemotherapy. We report a case of aggressive non-Hodgkin lymphoma refractory to first-line R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) and second-line R-DHAP (rituximab, dexamethasone, cytarabine, and cisplatin) chemotherapy treatments. The patient achieved remission with single-agent pixantrone, and received a consolidation with high-dose BEAM (BCNU, etoposide, cytarabine, and melphalan) chemotherapy and autologous stem cell transplantation. He received consolidation radiotherapy on the site of bulky disease. At 20 months from transplant, the disease is in continuous complete remission. The successful use of pixantrone as a bridge to transplant is highlighted, together with the absence of serious side effects.
- Published
- 2017